Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Clavenna

Ophthalmology West Des Moines, IA Doctor of Osteopathy

NPI 1831181627 CMS profile 37388

6200 Westown Pkwy, West Des Moines, IA 50266

Open in the dashboard

General payments

$3,872

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Clavenna of West Des Moines, IA is reported in the CMS Open Payments database as having received $3,872 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $634 16
2024 General $602 15
2023 General $656 20
2022 General $496 18
2021 General $312 16
2020 General $383 10
2019 General $789 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Clavenna
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to George Clavenna were reported at $634. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year George Clavenna Ophthalmology median Middle half National median
2019 $789 $258 $104–$655 $163
2020 $383 $126 $45–$321 $114
2021 $312 $205 $76–$534 $132
2022 $496 $266 $100–$678 $149
2023 $656 $308 $117–$745 $160
2024 $602 $340 $127–$846 $164
2025 $634 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $791 17 payments
  2. AbbVie, Inc. $618 9 payments
  3. Alcon Vision LLC $409 21 payments
  4. Bausch & Lomb Americas Inc. $290 13 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $290 7 payments
  6. Aerie Pharmaceuticals, Inc. $267 10 payments
  7. Sun Pharmaceutical Industries Inc. $224 13 payments
  8. Dompe US, Inc. $211 6 payments
  9. Mallinckrodt Hospital Products Inc. $210 5 payments
  10. Horizon Therapeutics plc $125 1 payment
  11. Other $436 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,774 110 payments
  2. Education $98 1 payment
Products named General payments · program years 2019–2025
  1. DURYSTA $469 4 payments
  2. rhopressa $417 17 payments
  3. rocklatan $394 15 payments
  4. LOTEMAX SM $283 10 payments
  5. LUMIGAN Eye Care $274 6 payments
  6. RESTASIS $266 7 payments
  7. LUMIGAN Ophthalmology $247 5 payments
  8. Cequa $224 13 payments
  9. OXERVATE $211 6 payments
  10. ACTHAR $210 5 payments
  11. Other $1,848 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,655

Median for Ophthalmology: 891

Drug cost

$276,736

Median for Ophthalmology: $68,233

Branded share of claims

40.4%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 162 $90,518
Restasis Cyclosporine Brand 60 $62,321
Rocklatan Netarsudil Mesylat/Latanoprost Brand 75 $30,838
Rhopressa Netarsudil Mesylate Brand 36 $15,043
Xiidra Lifitegrast Brand 17 $13,516
Miebo Perfluorohexyloctane/Pf Brand 14 $10,045
Combigan Brimonidine Tartrate/Timolol Brand 37 $9,831
Simbrinza Brinzolamide/Brimonidine Tart Brand 14 $7,925
Cyclosporine Generic 18 $6,313
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 36 $5,077

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$81,554

Medicare's payments for the services billed

Medicare patients

533

Average age 76

Services billed

1,096

317 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Diabetes 30%
Chronic kidney disease 26%
Depression 22%
Ischemic heart disease 21%
Osteoporosis 21%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $255
$255 — —
LUMIGAN
  • AbbVie, Inc. $118
$118 162 —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $69
$69 — —
Rocklatan
  • Alcon Vision LLC $46
$46 75 —
OXERVATE
  • Dompe US, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record